Business Context and Reporting Period
This Form 8-K Current Report, dated June 16, 2021, details the initial public offering (IPO) and related corporate governance changes for iSpecimen Inc., a Delaware corporation. The report covers events occurring between June 16, 2021, and June 21, 2021, including the entry into a material underwriting agreement, the conversion of debt and preferred equity, and the appointment of new directors.
Key Financial Metrics and Capital Structure
- IPO Proceeds: The Company sold 2,250,000 shares of Class A Common Stock at $8.00 per share, generating gross proceeds of $18,000,000.
- Over-Allotment Option: Underwriters were granted a 45-day option to purchase up to 337,500 additional shares.
- Debt Conversion (Convertible Notes): Outstanding principal and accrued interest totaling $6,757,066 were converted into 1,206,614 shares of common stock at $5.60 per share.
- Debt Conversion (Bridge Notes): Outstanding principal of $4,000,000 and accrued interest of $717,646 were converted into 842,429 shares of common stock at $5.60 per share.
- Preferred Stock Conversion: All outstanding Series A, Series A-1, and Series B Preferred Stock were converted into 1,291,012 shares of common stock.
Note: This filing does not provide revenue, profit, cash flow, or margin data. It focuses exclusively on capital raising and equity restructuring.
Material Changes Versus Prior Period
The primary material change is the Company's transition from a private entity to a public company listed on The Nasdaq Stock Market LLC under the symbol "ISPC." This transition involved:
- Elimination of significant debt obligations through automatic conversion into equity.
- Elimination of all outstanding preferred stock through conversion into common stock.
- Incorporation of new governance documents, including a Fourth Amended and Restated Certificate of Incorporation and Second Amended and Restated Bylaws.
Guidance, Outlook, and Corporate Actions
The filing does not contain forward-looking financial guidance or management commentary regarding future revenue or profitability. Key corporate actions include:
- Underwriting Agreement: Entered into with ThinkEquity, a division of Fordham Financial Management, Inc., as representative of the underwriters.
- Board Appointments: John L. Brooks III and Margaret H. Lawrence were appointed to the Board of Directors effective June 16, 2021.
- Regulatory Status: The Company is designated as an emerging growth company.
Investor Verification Checklist
- Verify the final closing date of the IPO (June 21, 2021) and the actual number of shares sold if the over-allotment option was exercised.
- Confirm the total dilution impact from the conversion of $6.76 million in Convertible Notes, $4.72 million in Bridge Notes, and all Preferred Stock.
- Review the Fourth Amended and Restated Certificate of Incorporation (Exhibit 3.1) for specific anti-takeover provisions or director liability limitations.
- Examine the Registration Statement (Form S-1, File No. 333-250198) for detailed financial statements, risk factors, and use of proceeds not included in this 8-K.